long-term effects of glp-1 receptor agonists Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Agonists: A Multidisciplinary Expert Consensus The Impact of Glucagon-like Peptide-1

Phase I and II clinical trials corroborate these findings, showing dose-dependent weight loss, reductions in Glycated Hemoglobin (HbA1c) levels, and improvements in liver steatosis and diabetic kidney disease

It also targets other cells in the pancreas to stop the glucagon signal for generating glucose in the liver.[ref] In clinical trials, GLP-1 RAs improved lipid profiles, increased satiety, slowed gastric emptying, reduced inflammation, and had neuroprotective effects.[ref] The slowing of gastric emptying and reducing inflammation may play a role in weight loss, along with the decrease in appetite and eating less

2017, p

The role of glucagon-like peptide-1 receptor agonists in chronic obstructive pulmonary disease

What Studies Show Early research suggests that CagriSema may help patients lose even more weight than semaglutide alone

Proteomic changes upon treatment with semaglutide in individuals with obesity